The Effect of Parathyroid Hormone on Osteogenesis Is Mediated Partly by Osteolectin Downloaded by Guest on September 28, 2021 INAUGURAL ARTICLE CELL BIOLOGY
The effect of parathyroid hormone on osteogenesis is INAUGURAL ARTICLE mediated partly by osteolectin Jingzhu Zhanga, Adi Cohenb, Bo Shena, Liming Dua, Alpaslan Tasdogana, Zhiyu Zhaoa, Elizabeth J. Shaneb, and Sean J. Morrisona,c,d,1 aChildren’s Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75235; bDepartment of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032; cHHMI, University of Texas Southwestern Medical Center, Dallas, TX 75235; and dDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235 This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2020. Contributed by Sean J. Morrison, April 16, 2021 (sent for review December 19, 2020; reviewed by Hank Kronenberg, Noriaki Ono, and Joy Y. Wu) We previously described a new osteogenic growth factor, osteo- use (14). Existing therapies include antiresorptive agents that slow lectin/Clec11a, which is required for the maintenance of skeletal bone loss, such as bisphosphonates (15, 16) and estrogens (17), bone mass during adulthood. Osteolectin binds to Integrin α11 and anabolic agents that increase bone formation, such as para- (Itga11), promoting Wnt pathway activation and osteogenic dif- thyroid hormone (PTH) (18), PTH-related protein (19), and ferentiation by leptin receptor+ (LepR+) stromal cells in the bone sclerostin inhibitor (SOSTi) (20). While these therapies increase marrow. Parathyroid hormone (PTH) and sclerostin inhibitor bone mass and reduce fracture risk, they are not a cure. (SOSTi) are bone anabolic agents that are administered to patients PTH promotes both anabolic and catabolic bone remodeling with osteoporosis.
[Show full text]